The Application of Phase 0 and Microtracer Approaches in Early Clinical Development: Past, Present, and Future

Overview

Journal Front Pharmacol

Date 2024 Apr 2

PMID 38562464

Authors

A F Roffel

E-J van Hoogdalem

Affiliations

Soon will be listed here.

Abstract

Phase 0 microdosing studies were introduced to the drug development community approximately 20 years ago. A microdose is defined as less than 1/100th of the dose calculated based on animal data to yield a pharmacological effect in humans, with a maximum of 100 μg, or 30 nmoles for protein products. In our experience, Phase 0 microdose studies have not been fully embraced by the pharmaceutical industry. This notion is based on the number of Phase 0 studies that we have been involved in. Thus, we conducted at least 17 Phase 0 microdose studies in the Zero's (on average, two per year), but in the years beyond this, it was only 15 studies (1.4 per year); in these latter years, we did conduct a total of 23 studies which employed an intravenous (i.v.) microdose for absolute bioavailability (ABA) assessments (two per year on average), which are the most used and potentially informative type of clinical study using a microdose, albeit they are formally not microdose studies. In the current review, we summarize the past use of and experience with Phase 0 microdose designs in early clinical development, including intravenous C microdose ABA studies, and assess what is needed to increase the adoption of useful applications of Phase 0/microdose studies in the near future.

References

Lappin G, Noveck R, Burt T . Microdosing and drug development: past, present and future. Expert Opin Drug Metab Toxicol. 2013; 9(7):817-34. PMC: 4532546. DOI: 10.1517/17425255.2013.786042. View

Lappin G, Boyce M, Matzow T, Lociuro S, Seymour M, Warrington S . A microdose study of ¹⁴C-AR-709 in healthy men: pharmacokinetics, absolute bioavailability and concentrations in key compartments of the lung. Eur J Clin Pharmacol. 2013; 69(9):1673-82. DOI: 10.1007/s00228-013-1528-2. View

Robinson W . Innovative early development regulatory approaches: expIND, expCTA, microdosing. Clin Pharmacol Ther. 2007; 83(2):358-60. DOI: 10.1038/sj.clpt.6100461. View

Muehlan C, Heuberger J, Juif P, Croft M, van Gerven J, Dingemanse J . Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study. Clin Pharmacol Ther. 2018; 104(5):1022-1029. DOI: 10.1002/cpt.1046. View

Boulton D, Kasichayanula S, Keung C, Arnold M, Christopher L, Xu X . Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. Br J Clin Pharmacol. 2012; 75(3):763-8. PMC: 3575942. DOI: 10.1111/j.1365-2125.2012.04391.x. View

Burt T, MacLeod D, Lee K, Santoro A, DeMasi D, Hawk T . Intra-Target Microdosing - A Novel Drug Development Approach: Proof of Concept, Safety, and Feasibility Study in Humans. Clin Transl Sci. 2017; 10(5):351-359. PMC: 5593161. DOI: 10.1111/cts.12477. View

Croft M, Keely B, Morris I, Tann L, Lappin G . Predicting drug candidate victims of drug-drug interactions, using microdosing. Clin Pharmacokinet. 2012; 51(4):237-46. DOI: 10.2165/11597070-000000000-00000. View

Dodd J, Jordan R, Makhlina M, Barnett K, Roffel A, Spana C . A novel oral formulation of the melanocortin-1 receptor agonist PL8177 resolves inflammation in preclinical studies of inflammatory bowel disease and is gut restricted in rats, dogs, and humans. Front Immunol. 2023; 14:1083333. PMC: 9986545. DOI: 10.3389/fimmu.2023.1083333. View

Ma S, Cho S, Sahasranaman S, Zhao W, Pang J, Ding X . Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent -Sparing PI3K Inhibitor in Rats, Dogs, and Humans. Drug Metab Dispos. 2023; 51(4):436-450. DOI: 10.1124/dmd.122.001096. View

10.

Lappin G, Shishikura Y, Jochemsen R, Weaver R, Gesson C, Houston B . Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci. 2010; 40(2):125-31. DOI: 10.1016/j.ejps.2010.03.009. View

11.

Young G, Spracklin D, James A, Hvenegaard M, Pedersen M, Wagner D . Non-Labeled, Stable Labeled, or Radiolabelled Approaches for Provision of Intravenous Pharmacokinetics in Humans: A Discussion Piece. Clin Pharmacol Ther. 2023; 115(5):931-938. DOI: 10.1002/cpt.3121. View

12.

Leonowens C, Pendry C, Bauman J, Young G, Ho M, Henriquez F . Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours. Br J Clin Pharmacol. 2014; 78(3):524-32. PMC: 4243903. DOI: 10.1111/bcp.12373. View

13.

Madan A, OBrien Z, Wen J, OBrien C, Farber R, Beaton G . A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects. Br J Clin Pharmacol. 2009; 67(3):288-98. PMC: 2675039. DOI: 10.1111/j.1365-2125.2008.03351.x. View

14.

Harrell A, Wilson R, Man Y, Riddell K, Jarvis E, Young G . An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects. Drug Metab Dispos. 2019; 47(12):1457-1468. DOI: 10.1124/dmd.119.088344. View

15.

Johne A, Scheible H, Becker A, Van Lier J, Wolna P, Meyring M . Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers. Invest New Drugs. 2020; 38(5):1507-1519. PMC: 7497692. DOI: 10.1007/s10637-020-00926-1. View

16.

Oesterreicher Z, Eberl S, Wulkersdorfer B, Matzneller P, Eder C, van Duijn E . Microdosing as a Potential Tool to Enhance Clinical Development of Novel Antibiotics: A Tissue and Plasma PK Feasibility Study with Ciprofloxacin. Clin Pharmacokinet. 2022; 61(5):697-707. PMC: 9095552. DOI: 10.1007/s40262-021-01091-1. View

17.

Zhang W, Colburn D, Simmons B, Papai Z, Bertran E, Schadt S . Absolute Bioavailability of Vemurafenib in Patients With BRAF Mutation-Positive Malignancies. Clin Pharmacol Drug Dev. 2020; 9(4):496-504. DOI: 10.1002/cpdd.773. View

18.

Burt T, Young G, Lee W, Kusuhara H, Langer O, Rowland M . Phase 0/microdosing approaches: time for mainstream application in drug development?. Nat Rev Drug Discov. 2020; 19(11):801-818. DOI: 10.1038/s41573-020-0080-x. View

19.

Burt T, Roffel A, Langer O, Anderson K, DiMasi J . Strategic, feasibility, economic, and cultural aspects of phase 0 approaches: Is it time to change the drug development process in order to increase productivity?. Clin Transl Sci. 2022; 15(6):1355-1379. PMC: 9199889. DOI: 10.1111/cts.13269. View

20.

. Radiological Protection in Biomedical Research. A report of Committee 3 adopted by the International Commission on Radiological Protection. Ann ICRP. 1991; 22(3):1-28, v-xxiv. View